Literature DB >> 17885669

Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.

Mikhail Lisovsky1, Mai P Hoang, Karen A Dresser, Payal Kapur, Jag Bhawan, Meera Mahalingam.   

Abstract

More recent techniques to characterize the genetic profile of soft-tissue tumors include the use of gene arrays. Using this technique, Apolipoprotein D (Apo D), a 33-kDa glycoprotein component of high-density lipoprotein, has been found to be highly expressed in dermatofibrosarcoma protuberans. To corroborate these results, we sought to ascertain the utility of Apo D by investigating its sensitivity and specificity in a variety of CD34-positive and CD34-negative cutaneous neoplasms including superficial acral fibromyxoma, sclerotic fibromas, and cellular dermatofibromas. Of interest, we found absence of Apo D expression in all four cases of superficial acral fibromyxoma. Of the remaining CD34-positive lesions, Apo D expression was noted in 35/36 (97%) cases of dermatofibrosarcoma protuberans, 3/5 (60%) giant-cell fibroblastomas, 4/4 (100%) sclerotic fibromas, 8/8 (100%) neurofibromas, and 1/1 (100%) solitary fibrous tumor. Of the CD34-negative lesions, Apo D expression was noted in 2/22 (9%) regular dermatofibroma, 23/45 (51%) cellular dermatofibroma, 10/10 (100%) malignant fibrous histiocytoma, 9/10 (90%) atypical fibroxanthoma, 7/8 (86%) cellular neurothekeoma, 9/9 (100%) malignant melanoma, 8/8 (100%) melanocytic nevi (100%), 0/2 superficial angiomyxoma, 0/15 fibromatosis, 0/1 nodular fasciitis, and 1/2 (50%) desmoplastic fibroblastomas. In summary, our findings indicate that Apo D expression is not specific to dermatofibrosarcoma protuberans. Its principal use as an immunohistochemical adjunct lies in its utility in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Although strong positive staining of Apo D in a markedly atypical fibrohistiocytic lesion is suggestive of atypical fibroxanthoma and/or malignant fibrous histiocytoma, further studies with the inclusion of other atypical spindled cell neoplasms are required to conclusively prove the same.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885669     DOI: 10.1038/modpathol.3800971

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  4 in total

1.  Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications.

Authors:  Steven D Forsythe; Hemamylammal Sivakumar; Richard A Erali; Nadeem Wajih; Wencheng Li; Perry Shen; Edward A Levine; Katherine E Miller; Aleksander Skardal; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2022-07-03       Impact factor: 4.339

Review 2.  Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations.

Authors:  Cyril Fisher
Journal:  Virchows Arch       Date:  2009-04-28       Impact factor: 4.064

3.  Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans.

Authors:  Xiao Zhang; Di Sun; Haiyan Zheng; Yamin Rao; Yuqi Deng; Xiao Liang; Jun Chen; Jun Yang
Journal:  Front Genet       Date:  2022-09-05       Impact factor: 4.772

4.  Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans.

Authors:  Emanuela Palmerini; Marco Gambarotti; Eric L Staals; Licciana Zanella; Gabriela Sieberova; Alessandra Longhi; Marilena Cesari; Stefano Bonarelli; Piero Picci; Pietro Ruggieri; Marco Alberghini; Stefano Ferrari
Journal:  Clin Sarcoma Res       Date:  2012-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.